AstraZeneca wins EU Enhertu approval and stock costs EUR 154.10

Published on 10/29/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EU approval expands Enhertu into early breast cancer treatment. AstraZeneca stock costs EUR 154.10 on October 29, 2026 at Lang & Schwarz.

Enhertu expands its European role

The European Union approved Enhertu for residual HER2-positive early breast cancer on October 27, 2026.
DESTINY-Breast05 showed a 53 percent reduction in invasive disease recurrence or death.
AstraZeneca stock trades at EUR 154.10 at 10:10 a.m. CET at Lang & Schwarz on October 29, 2026.
Three-year invasive disease-free survival reached 92.40 percent with Enhertu versus 83.70 percent with T-DM1.
AstraZeneca lists nine-month and third-quarter 2026 results for October 30, 2026.

AstraZeneca, GB0009895292, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) secured European Union approval for Enhertu in adjuvant treatment of adults with residual HER2-positive early breast cancer on October 27, 2026. The decision expands the medicine into a curative-intent setting, while AstraZeneca stock costs EUR 154.10 at Lang & Schwarz on October 29, 2026 at 10:10 a.m. CET.

EU approval expands early use

According to AstraZeneca, the European Commission authorization covers patients whose disease remains after neoadjuvant taxane-based and HER2-targeted treatment. The approval is based on the DESTINY-Breast05 Phase III trial and represents the first European Union approval of Enhertu in early breast cancer.

The commercial detail is material: AstraZeneca owes Daiichi Sankyo USD 75.00 million as a milestone payment following the approval, while sales in most European Union territories are recognized by Daiichi Sankyo, according to the October 27 release from AstraZeneca.

What does the trial show?

DESTINY-Breast05 enrolled 1,635 patients and showed a 53 percent reduction in invasive disease recurrence or death versus T-DM1. Three-year invasive disease-free survival was 92.40 percent with Enhertu compared with 83.70 percent with T-DM1, giving the approval a measurable clinical basis.

Next company date

AstraZeneca's investor-relations calendar lists nine-month and third-quarter 2026 results for October 30, 2026, followed by a London roadshow on November 2, 2026. Those dates place the new European approval alongside the next financial update.

Stock remains tied to the pipeline

The Enhertu decision adds a new early-stage breast-cancer indication to AstraZeneca's oncology portfolio. The company says Enhertu is jointly developed and commercialized with Daiichi Sankyo, making regulatory expansion relevant to both the clinical pipeline and the partnership economics.

AstraZeneca stock was trading at EUR 154.10 at Lang & Schwarz on October 29, 2026 at 10:10 a.m. CET. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.